Fondaparinux – data on efficacy and safety in special situations.

Link to article at PubMed

Fondaparinux - data on efficacy and safety in special situations.

Thromb Res. 2011 Nov 29;

Authors: Nagler M, Haslauer M, Wuillemin WA

Abstract
New anticoagulants promise to have better efficacy, more safety and/or a better manageability than traditional anticoagulants. However, knowledge is limited regarding special situations such as renal insufficiency, obesity, pregnancy, long-term therapy, heparin-induced thrombocytopenia, treatment in patients with mechanical heart valves, use for children, and in patients with a high risk of thromboembolic complications. These situations have rarely or even never been the objective of randomised controlled trials. The purpose of the present article is to summarize and discuss available data on efficacy and safety in these special situations for one of the first new anticoagulants, the indirect factor-Xa inhibitor fondaparinux. Furthermore, we discuss safety in licensed indications and management of bleeding complications and comment on measuring of drug concentration in plasma.

PMID: 22133273 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.